Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C (2020)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
Scand J Gastroenterol, 55 (8), 884-890
DOI 10.1080/00365521.2020.1786852, PubMed 32631131

Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T (2019)
Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease
JGH Open, 4 (3), 410-416
DOI 10.1002/jgh3.12266, PubMed 32514446